RU2018126958A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018126958A3 RU2018126958A3 RU2018126958A RU2018126958A RU2018126958A3 RU 2018126958 A3 RU2018126958 A3 RU 2018126958A3 RU 2018126958 A RU2018126958 A RU 2018126958A RU 2018126958 A RU2018126958 A RU 2018126958A RU 2018126958 A3 RU2018126958 A3 RU 2018126958A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/42—One nitrogen atom
- C07D251/44—One nitrogen atom with halogen atoms attached to the two other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/42—One nitrogen atom
- C07D251/46—One nitrogen atom with oxygen or sulfur atoms attached to the two other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
- C07D251/50—Two nitrogen atoms with a halogen atom attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
- C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/54—Three nitrogen atoms
- C07D251/70—Other substituted melamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562387590P | 2015-12-24 | 2015-12-24 | |
| US62/387,590 | 2015-12-24 | ||
| PCT/US2016/068569 WO2017112951A1 (en) | 2015-12-24 | 2016-12-23 | Cftr regulators and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018126958A RU2018126958A (ru) | 2020-01-27 |
| RU2018126958A3 true RU2018126958A3 (ru) | 2020-03-10 |
| RU2749834C2 RU2749834C2 (ru) | 2021-06-17 |
Family
ID=59091271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018126958A RU2749834C2 (ru) | 2015-12-24 | 2016-12-23 | Кфтр регуляторы и способы их применения |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US10604492B2 (ru) |
| EP (2) | EP4019501A1 (ru) |
| JP (2) | JP6938510B2 (ru) |
| KR (1) | KR102733897B1 (ru) |
| CN (2) | CN108848668B (ru) |
| AU (1) | AU2016379444B2 (ru) |
| BR (1) | BR112018012949B1 (ru) |
| CA (1) | CA3009510A1 (ru) |
| CL (1) | CL2018001715A1 (ru) |
| CO (1) | CO2018007237A2 (ru) |
| DK (1) | DK3394040T3 (ru) |
| ES (1) | ES2909316T3 (ru) |
| IL (1) | IL260208B2 (ru) |
| MX (2) | MX383072B (ru) |
| PL (1) | PL3394040T3 (ru) |
| PT (1) | PT3394040T (ru) |
| RU (1) | RU2749834C2 (ru) |
| WO (1) | WO2017112951A1 (ru) |
| ZA (1) | ZA201804230B (ru) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3394040T3 (pl) * | 2015-12-24 | 2022-05-02 | The Regents Of The University Of California | Regulatory cftr i sposoby ich zastosowania |
| EP3672598A4 (en) * | 2017-08-24 | 2021-04-28 | The Regents of The University of California | MEDICINAL COMPOSITIONS FOR THE EYE |
| FR3096890B1 (fr) * | 2019-06-07 | 2021-05-14 | H4 Orphan Pharma | Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique. |
| BR112022010871A2 (pt) | 2019-12-05 | 2022-08-23 | Vanda Pharmaceuticals Inc | Composições farmacêuticas oftalmológicas |
| WO2022056265A1 (en) | 2020-09-10 | 2022-03-17 | Vanda Pharmaceuticals Inc. | Methods of treating pde iv-mediated diseases or conditions |
| WO2025179141A1 (en) | 2024-02-22 | 2025-08-28 | Vanda Pharmaceuticals, Inc. | Treatment of dry eye disease |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK35124C (da) | 1924-03-19 | 1925-10-12 | Niels Christian Carl S Nielsen | Anordning ved Ægisolatorer og lignende. |
| DK72517C (da) | 1948-04-08 | 1951-05-15 | Hans Dr Ing Wolf | Kobling til paralleldrift af vekselstrømsmotorer. |
| DK101373C (da) | 1962-03-16 | 1965-03-29 | Hoechst Ag | Fremgangsmåde til fremstilling af vandopløselige monoazofarvestoffer. |
| ZA794209B (en) | 1978-08-15 | 1980-07-30 | Fisons Ltd | Pharmaceutically active heterocyclic compounds |
| EP0008864A1 (en) | 1978-08-15 | 1980-03-19 | FISONS plc | Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them |
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| JPS62126178A (ja) * | 1985-11-26 | 1987-06-08 | Mitsubishi Petrochem Co Ltd | 新規トリアジン誘導体及びこれを含む除草剤 |
| US5236952A (en) | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| WO1994011355A1 (fr) | 1992-11-19 | 1994-05-26 | Dainippon Pharmaceutical Co., Ltd. | Derive de 3,4-dihydro-1(2-hydroxyphenyl)-2(1h)-quinoxalinone et compose associe |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| WO1999038497A2 (en) | 1998-01-30 | 1999-08-05 | R-Tech Ueno, Ltd. | Ophthalmic composition |
| EP0945447A1 (en) | 1998-03-27 | 1999-09-29 | Janssen Pharmaceutica N.V. | Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections |
| GB9806739D0 (en) | 1998-03-28 | 1998-05-27 | Univ Newcastle Ventures Ltd | Cyclin dependent kinase inhibitors |
| KR20010042298A (ko) | 1998-03-31 | 2001-05-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 인자 Ｘａ 및 트롬빈과 같은 세린 프로테아제억제제로서의 퀴녹살리논 |
| WO2001047897A1 (en) * | 1999-12-28 | 2001-07-05 | Pharmacopeia, Inc. | Cytokine, especially tnf-alpha, inhibitors |
| RS34004A (sr) | 2001-09-21 | 2006-10-27 | Reddy Us Therapeutics Inc. | Postupci i sastavi novih triazin jedinjenja |
| US7163943B2 (en) * | 2001-09-21 | 2007-01-16 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
| AU2003272740A1 (en) * | 2002-10-01 | 2004-04-23 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 4,6-diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors |
| CA2533397A1 (en) | 2003-07-22 | 2005-02-03 | Neurogen Corporation | Substituted pyridin-2-ylamine analogues |
| US8759335B2 (en) | 2004-01-30 | 2014-06-24 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| US7335770B2 (en) * | 2004-03-24 | 2008-02-26 | Reddy U5 Therapeutics, Inc. | Triazine compounds and their analogs, compositions, and methods |
| DE102004023332A1 (de) | 2004-05-12 | 2006-01-19 | Bayer Cropscience Gmbh | Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung |
| BRPI0608453A2 (pt) * | 2005-03-18 | 2009-12-29 | Univ California | compostos tendo atividade na correção de processamento de cftr mutante e usos destes |
| WO2007095812A1 (en) | 2006-02-27 | 2007-08-30 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Substituted [1,3,5] triazine compounds, their processes for preparation and uses thereof |
| CN104606194A (zh) * | 2006-07-07 | 2015-05-13 | S·P·戈瓦克 | Pde4的双环杂芳基抑制剂 |
| PT2149560E (pt) * | 2007-05-22 | 2015-07-13 | Astellas Pharma Inc | Composto de tetra-hidroisoquinolina substituído na posição 1 |
| US20090105240A1 (en) | 2007-10-17 | 2009-04-23 | Tomas Mustelin | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same |
| WO2009091388A2 (en) * | 2007-12-21 | 2009-07-23 | Progenics Pharmaceuticals, Inc. | Triazines and related compounds having antiviral activity, compositions and methods thereof |
| JP5618837B2 (ja) | 2008-03-05 | 2014-11-05 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | インスリン分泌刺激剤としてのキノキサリノン誘導体、それらを得る方法および糖尿病を治療するためのそれらの使用 |
| AU2009308232B2 (en) | 2008-10-23 | 2016-02-04 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2010073011A2 (en) | 2008-12-23 | 2010-07-01 | Betagenon Ab | Compounds useful as medicaments |
| US8476442B2 (en) * | 2009-03-20 | 2013-07-02 | Vertex Pharmaceutical Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
| FR2958645B1 (fr) | 2010-04-09 | 2012-08-31 | Commissariat Energie Atomique | Hemi-anticorps a auto-assemblage |
| CN105130948A (zh) * | 2010-04-22 | 2015-12-09 | 弗特克斯药品有限公司 | 制备环烷基甲酰胺基-吲哚化合物的方法 |
| WO2012092471A2 (en) | 2010-12-29 | 2012-07-05 | Development Center For Biotechnology | Novel tubulin inhibitors and methods of using the same |
| WO2014097147A1 (en) | 2012-12-19 | 2014-06-26 | Novartis Ag | Tricyclic compounds as cftr inhibitors |
| HUE040366T2 (hu) | 2013-08-08 | 2019-03-28 | Galapagos Nv | CFTR modulátor tieno[2,3-c]piránok |
| WO2015168079A1 (en) | 2014-04-29 | 2015-11-05 | Infinity Pharmaceuticals, Inc. | Pyrimidine or pyridine derivatives useful as pi3k inhibitors |
| CN108028168B (zh) | 2015-09-11 | 2021-03-30 | 约恩托福技术有限公司 | 二次离子质谱仪和二次离子质谱法 |
| RS64703B1 (sr) | 2015-12-24 | 2023-11-30 | Respivert Ltd | Jedinjenja indolinona i njihova upotreba u lečenju fibroznih bolesti |
| BR112018012927A2 (pt) | 2015-12-24 | 2018-12-11 | Univ California | reguladores cftr e métodos de uso dos mesmos |
| PL3394040T3 (pl) | 2015-12-24 | 2022-05-02 | The Regents Of The University Of California | Regulatory cftr i sposoby ich zastosowania |
| EP3394046B1 (en) | 2015-12-24 | 2022-03-09 | The Regents Of The University Of California | Cftr regulators and methods of use thereof |
| EP3672598A4 (en) | 2017-08-24 | 2021-04-28 | The Regents of The University of California | MEDICINAL COMPOSITIONS FOR THE EYE |
| JP7256631B2 (ja) | 2018-11-01 | 2023-04-12 | 株式会社豊田中央研究所 | 距離測定装置 |
-
2016
- 2016-12-23 PL PL16880160T patent/PL3394040T3/pl unknown
- 2016-12-23 WO PCT/US2016/068569 patent/WO2017112951A1/en not_active Ceased
- 2016-12-23 JP JP2018533169A patent/JP6938510B2/ja active Active
- 2016-12-23 IL IL260208A patent/IL260208B2/en unknown
- 2016-12-23 EP EP21207338.1A patent/EP4019501A1/en active Pending
- 2016-12-23 CN CN201680082483.1A patent/CN108848668B/zh active Active
- 2016-12-23 RU RU2018126958A patent/RU2749834C2/ru active
- 2016-12-23 US US16/016,290 patent/US10604492B2/en active Active
- 2016-12-23 DK DK16880160.3T patent/DK3394040T3/da active
- 2016-12-23 EP EP16880160.3A patent/EP3394040B1/en active Active
- 2016-12-23 CN CN202210373667.0A patent/CN115710233A/zh active Pending
- 2016-12-23 BR BR112018012949-6A patent/BR112018012949B1/pt active IP Right Grant
- 2016-12-23 ES ES16880160T patent/ES2909316T3/es active Active
- 2016-12-23 KR KR1020187021208A patent/KR102733897B1/ko active Active
- 2016-12-23 MX MX2018007767A patent/MX383072B/es unknown
- 2016-12-23 CA CA3009510A patent/CA3009510A1/en active Pending
- 2016-12-23 PT PT168801603T patent/PT3394040T/pt unknown
- 2016-12-23 AU AU2016379444A patent/AU2016379444B2/en active Active
-
2018
- 2018-06-21 CL CL2018001715A patent/CL2018001715A1/es unknown
- 2018-06-22 MX MX2021006439A patent/MX2021006439A/es unknown
- 2018-06-22 ZA ZA201804230A patent/ZA201804230B/en unknown
- 2018-07-11 CO CONC2018/0007237A patent/CO2018007237A2/es unknown
-
2020
- 2020-02-07 US US16/785,417 patent/US11230535B2/en active Active
-
2021
- 2021-08-31 JP JP2021140812A patent/JP7297827B2/ja active Active
- 2021-11-23 US US17/456,368 patent/US20220081402A1/en not_active Abandoned
-
2023
- 2023-05-11 US US18/316,183 patent/US12065412B2/en active Active
-
2024
- 2024-05-31 US US18/731,154 patent/US12391654B2/en active Active